Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
Tisotumab vedotin is a first-in-human antibody–drug conjugate directed against tissue factor, which is expressed across multiple solid tumour types and is associated with poor clinical outcomes. We aimed to establish the safety, tolerability, pharmacokinetic profile, and antitumour activity of tisot...
Uložené v:
| Vydané v: | The lancet oncology Ročník 20; číslo 3; s. 383 - 393 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
England
Elsevier Ltd
01.03.2019
Elsevier Limited |
| Predmet: | |
| ISSN: | 1470-2045, 1474-5488, 1474-5488 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Tisotumab vedotin is a first-in-human antibody–drug conjugate directed against tissue factor, which is expressed across multiple solid tumour types and is associated with poor clinical outcomes. We aimed to establish the safety, tolerability, pharmacokinetic profile, and antitumour activity of tisotumab vedotin in a mixed population of patients with locally advanced or metastatic (or both) solid tumours known to express tissue factor.
InnovaTV 201 is a phase 1–2, open-label, dose-escalation and dose-expansion study done at 21 centres in the USA and Europe. Patients (aged ≥18 years) had relapsed, advanced, or metastatic cancer of the ovary, cervix, endometrium, bladder, prostate, oesophagus, squamous cell carcinoma of the head and neck or non-small-cell lung cancer; an Eastern Cooperative Oncology Group performance status of 0–1; and had relapsed after or were not eligible to receive the available standard of care. No specific tissue factor expression level was required for inclusion. In the dose-escalation phase, patients were treated with tisotumab vedotin between 0·3 and 2·2 mg/kg intravenously once every 3 weeks in a traditional 3 + 3 design. In the dose-expansion phase, patients were treated at the recommended phase 2 dose. The primary endpoint was the incidence of adverse events, including serious adverse events, infusion-related, treatment-related and those of grade 3 or worse, and study drug-related adverse events, analysed in all patients who received at least one dose of tisotumab vedotin (full analysis population). This trial is registered with ClinicalTrials.gov, number NCT02001623, and is closed to new participants with follow-up ongoing.
Between Dec 9, 2013, and May 18, 2015, 27 eligible patients were enrolled to the dose-escalation phase. Dose-limiting toxicities, including grade 3 type 2 diabetes mellitus, mucositis, and neutropenic fever, were seen at the 2·2 mg/kg dose; therefore, 2·0 mg/kg of tisotumab vedotin intravenously once every 3 weeks was established as the recommended phase 2 dose. Between Oct 8, 2015, and April 26, 2018, 147 eligible patients were enrolled to the dose-expansion phase. The most common (in ≥20% of patients) treatment-emergent adverse events of any grade were epistaxis (102 [69%] of 147 patients), fatigue (82 [56%]), nausea (77 [52%]), alopecia (64 [44%]), conjunctivitis (63 [43%]), decreased appetite (53 [36%]), constipation (52 [35%]), diarrhoea (44 [30%]), vomiting (42 [29%]), peripheral neuropathy (33 [22%]), dry eye (32 [22%]), and abdominal pain (30 [20%]). The most common adverse events of grade 3 or worse were fatigue (14 [10%] of 147 patients), anaemia (eight [5%]), abdominal pain (six [4%]), hypokalaemia (six [4%]), conjunctivitis (five [3%]), hyponatraemia (five [3%]), and vomiting (five [3%]). 67 (46%) of 147 patients had a treatment-emergent serious adverse event. 39 (27%) of 147 patients had a treatment-emergent serious adverse event related to the study drug. Infusion-related reactions occurred in 17 (12%) of 147 patients. Across tumour types, the confirmed proportion of patients who achieved an objective response was 15·6% (95% CI 10·2–22·5; 23 of 147 patients). There were nine deaths across all study phases (three in the dose-escalation phase and six in the dose-expansion phase); only one case of pneumonia in the dose-expansion phase was considered possibly related to study treatment.
Tisotumab vedotin has a manageable safety profile with encouraging preliminary antitumour activity across multiple tumour types in heavily pretreated patients. Continued evaluation of tisotumab vedotin is warranted in solid tumours.
Genmab A/S. |
|---|---|
| AbstractList | Tisotumab vedotin is a first-in-human antibody-drug conjugate directed against tissue factor, which is expressed across multiple solid tumour types and is associated with poor clinical outcomes. We aimed to establish the safety, tolerability, pharmacokinetic profile, and antitumour activity of tisotumab vedotin in a mixed population of patients with locally advanced or metastatic (or both) solid tumours known to express tissue factor.
InnovaTV 201 is a phase 1-2, open-label, dose-escalation and dose-expansion study done at 21 centres in the USA and Europe. Patients (aged ≥18 years) had relapsed, advanced, or metastatic cancer of the ovary, cervix, endometrium, bladder, prostate, oesophagus, squamous cell carcinoma of the head and neck or non-small-cell lung cancer; an Eastern Cooperative Oncology Group performance status of 0-1; and had relapsed after or were not eligible to receive the available standard of care. No specific tissue factor expression level was required for inclusion. In the dose-escalation phase, patients were treated with tisotumab vedotin between 0·3 and 2·2 mg/kg intravenously once every 3 weeks in a traditional 3 + 3 design. In the dose-expansion phase, patients were treated at the recommended phase 2 dose. The primary endpoint was the incidence of adverse events, including serious adverse events, infusion-related, treatment-related and those of grade 3 or worse, and study drug-related adverse events, analysed in all patients who received at least one dose of tisotumab vedotin (full analysis population). This trial is registered with ClinicalTrials.gov, number NCT02001623, and is closed to new participants with follow-up ongoing.
Between Dec 9, 2013, and May 18, 2015, 27 eligible patients were enrolled to the dose-escalation phase. Dose-limiting toxicities, including grade 3 type 2 diabetes mellitus, mucositis, and neutropenic fever, were seen at the 2·2 mg/kg dose; therefore, 2·0 mg/kg of tisotumab vedotin intravenously once every 3 weeks was established as the recommended phase 2 dose. Between Oct 8, 2015, and April 26, 2018, 147 eligible patients were enrolled to the dose-expansion phase. The most common (in ≥20% of patients) treatment-emergent adverse events of any grade were epistaxis (102 [69%] of 147 patients), fatigue (82 [56%]), nausea (77 [52%]), alopecia (64 [44%]), conjunctivitis (63 [43%]), decreased appetite (53 [36%]), constipation (52 [35%]), diarrhoea (44 [30%]), vomiting (42 [29%]), peripheral neuropathy (33 [22%]), dry eye (32 [22%]), and abdominal pain (30 [20%]). The most common adverse events of grade 3 or worse were fatigue (14 [10%] of 147 patients), anaemia (eight [5%]), abdominal pain (six [4%]), hypokalaemia (six [4%]), conjunctivitis (five [3%]), hyponatraemia (five [3%]), and vomiting (five [3%]). 67 (46%) of 147 patients had a treatment-emergent serious adverse event. 39 (27%) of 147 patients had a treatment-emergent serious adverse event related to the study drug. Infusion-related reactions occurred in 17 (12%) of 147 patients. Across tumour types, the confirmed proportion of patients who achieved an objective response was 15·6% (95% CI 10·2-22·5; 23 of 147 patients). There were nine deaths across all study phases (three in the dose-escalation phase and six in the dose-expansion phase); only one case of pneumonia in the dose-expansion phase was considered possibly related to study treatment.
Tisotumab vedotin has a manageable safety profile with encouraging preliminary antitumour activity across multiple tumour types in heavily pretreated patients. Continued evaluation of tisotumab vedotin is warranted in solid tumours.
Genmab A/S. SummaryBackgroundTisotumab vedotin is a first-in-human antibody–drug conjugate directed against tissue factor, which is expressed across multiple solid tumour types and is associated with poor clinical outcomes. We aimed to establish the safety, tolerability, pharmacokinetic profile, and antitumour activity of tisotumab vedotin in a mixed population of patients with locally advanced or metastatic (or both) solid tumours known to express tissue factor. MethodsInnovaTV 201 is a phase 1–2, open-label, dose-escalation and dose-expansion study done at 21 centres in the USA and Europe. Patients (aged ≥18 years) had relapsed, advanced, or metastatic cancer of the ovary, cervix, endometrium, bladder, prostate, oesophagus, squamous cell carcinoma of the head and neck or non-small-cell lung cancer; an Eastern Cooperative Oncology Group performance status of 0–1; and had relapsed after or were not eligible to receive the available standard of care. No specific tissue factor expression level was required for inclusion. In the dose-escalation phase, patients were treated with tisotumab vedotin between 0·3 and 2·2 mg/kg intravenously once every 3 weeks in a traditional 3 + 3 design. In the dose-expansion phase, patients were treated at the recommended phase 2 dose. The primary endpoint was the incidence of adverse events, including serious adverse events, infusion-related, treatment-related and those of grade 3 or worse, and study drug-related adverse events, analysed in all patients who received at least one dose of tisotumab vedotin (full analysis population). This trial is registered with ClinicalTrials.gov, number NCT02001623, and is closed to new participants with follow-up ongoing. FindingsBetween Dec 9, 2013, and May 18, 2015, 27 eligible patients were enrolled to the dose-escalation phase. Dose-limiting toxicities, including grade 3 type 2 diabetes mellitus, mucositis, and neutropenic fever, were seen at the 2·2 mg/kg dose; therefore, 2·0 mg/kg of tisotumab vedotin intravenously once every 3 weeks was established as the recommended phase 2 dose. Between Oct 8, 2015, and April 26, 2018, 147 eligible patients were enrolled to the dose-expansion phase. The most common (in ≥20% of patients) treatment-emergent adverse events of any grade were epistaxis (102 [69%] of 147 patients), fatigue (82 [56%]), nausea (77 [52%]), alopecia (64 [44%]), conjunctivitis (63 [43%]), decreased appetite (53 [36%]), constipation (52 [35%]), diarrhoea (44 [30%]), vomiting (42 [29%]), peripheral neuropathy (33 [22%]), dry eye (32 [22%]), and abdominal pain (30 [20%]). The most common adverse events of grade 3 or worse were fatigue (14 [10%] of 147 patients), anaemia (eight [5%]), abdominal pain (six [4%]), hypokalaemia (six [4%]), conjunctivitis (five [3%]), hyponatraemia (five [3%]), and vomiting (five [3%]). 67 (46%) of 147 patients had a treatment-emergent serious adverse event. 39 (27%) of 147 patients had a treatment-emergent serious adverse event related to the study drug. Infusion-related reactions occurred in 17 (12%) of 147 patients. Across tumour types, the confirmed proportion of patients who achieved an objective response was 15·6% (95% CI 10·2–22·5; 23 of 147 patients). There were nine deaths across all study phases (three in the dose-escalation phase and six in the dose-expansion phase); only one case of pneumonia in the dose-expansion phase was considered possibly related to study treatment. InterpretationsTisotumab vedotin has a manageable safety profile with encouraging preliminary antitumour activity across multiple tumour types in heavily pretreated patients. Continued evaluation of tisotumab vedotin is warranted in solid tumours. FundingGenmab A/S. Tisotumab vedotin is a first-in-human antibody-drug conjugate directed against tissue factor, which is expressed across multiple solid tumour types and is associated with poor clinical outcomes. We aimed to establish the safety, tolerability, pharmacokinetic profile, and antitumour activity of tisotumab vedotin in a mixed population of patients with locally advanced or metastatic (or both) solid tumours known to express tissue factor.BACKGROUNDTisotumab vedotin is a first-in-human antibody-drug conjugate directed against tissue factor, which is expressed across multiple solid tumour types and is associated with poor clinical outcomes. We aimed to establish the safety, tolerability, pharmacokinetic profile, and antitumour activity of tisotumab vedotin in a mixed population of patients with locally advanced or metastatic (or both) solid tumours known to express tissue factor.InnovaTV 201 is a phase 1-2, open-label, dose-escalation and dose-expansion study done at 21 centres in the USA and Europe. Patients (aged ≥18 years) had relapsed, advanced, or metastatic cancer of the ovary, cervix, endometrium, bladder, prostate, oesophagus, squamous cell carcinoma of the head and neck or non-small-cell lung cancer; an Eastern Cooperative Oncology Group performance status of 0-1; and had relapsed after or were not eligible to receive the available standard of care. No specific tissue factor expression level was required for inclusion. In the dose-escalation phase, patients were treated with tisotumab vedotin between 0·3 and 2·2 mg/kg intravenously once every 3 weeks in a traditional 3 + 3 design. In the dose-expansion phase, patients were treated at the recommended phase 2 dose. The primary endpoint was the incidence of adverse events, including serious adverse events, infusion-related, treatment-related and those of grade 3 or worse, and study drug-related adverse events, analysed in all patients who received at least one dose of tisotumab vedotin (full analysis population). This trial is registered with ClinicalTrials.gov, number NCT02001623, and is closed to new participants with follow-up ongoing.METHODSInnovaTV 201 is a phase 1-2, open-label, dose-escalation and dose-expansion study done at 21 centres in the USA and Europe. Patients (aged ≥18 years) had relapsed, advanced, or metastatic cancer of the ovary, cervix, endometrium, bladder, prostate, oesophagus, squamous cell carcinoma of the head and neck or non-small-cell lung cancer; an Eastern Cooperative Oncology Group performance status of 0-1; and had relapsed after or were not eligible to receive the available standard of care. No specific tissue factor expression level was required for inclusion. In the dose-escalation phase, patients were treated with tisotumab vedotin between 0·3 and 2·2 mg/kg intravenously once every 3 weeks in a traditional 3 + 3 design. In the dose-expansion phase, patients were treated at the recommended phase 2 dose. The primary endpoint was the incidence of adverse events, including serious adverse events, infusion-related, treatment-related and those of grade 3 or worse, and study drug-related adverse events, analysed in all patients who received at least one dose of tisotumab vedotin (full analysis population). This trial is registered with ClinicalTrials.gov, number NCT02001623, and is closed to new participants with follow-up ongoing.Between Dec 9, 2013, and May 18, 2015, 27 eligible patients were enrolled to the dose-escalation phase. Dose-limiting toxicities, including grade 3 type 2 diabetes mellitus, mucositis, and neutropenic fever, were seen at the 2·2 mg/kg dose; therefore, 2·0 mg/kg of tisotumab vedotin intravenously once every 3 weeks was established as the recommended phase 2 dose. Between Oct 8, 2015, and April 26, 2018, 147 eligible patients were enrolled to the dose-expansion phase. The most common (in ≥20% of patients) treatment-emergent adverse events of any grade were epistaxis (102 [69%] of 147 patients), fatigue (82 [56%]), nausea (77 [52%]), alopecia (64 [44%]), conjunctivitis (63 [43%]), decreased appetite (53 [36%]), constipation (52 [35%]), diarrhoea (44 [30%]), vomiting (42 [29%]), peripheral neuropathy (33 [22%]), dry eye (32 [22%]), and abdominal pain (30 [20%]). The most common adverse events of grade 3 or worse were fatigue (14 [10%] of 147 patients), anaemia (eight [5%]), abdominal pain (six [4%]), hypokalaemia (six [4%]), conjunctivitis (five [3%]), hyponatraemia (five [3%]), and vomiting (five [3%]). 67 (46%) of 147 patients had a treatment-emergent serious adverse event. 39 (27%) of 147 patients had a treatment-emergent serious adverse event related to the study drug. Infusion-related reactions occurred in 17 (12%) of 147 patients. Across tumour types, the confirmed proportion of patients who achieved an objective response was 15·6% (95% CI 10·2-22·5; 23 of 147 patients). There were nine deaths across all study phases (three in the dose-escalation phase and six in the dose-expansion phase); only one case of pneumonia in the dose-expansion phase was considered possibly related to study treatment.FINDINGSBetween Dec 9, 2013, and May 18, 2015, 27 eligible patients were enrolled to the dose-escalation phase. Dose-limiting toxicities, including grade 3 type 2 diabetes mellitus, mucositis, and neutropenic fever, were seen at the 2·2 mg/kg dose; therefore, 2·0 mg/kg of tisotumab vedotin intravenously once every 3 weeks was established as the recommended phase 2 dose. Between Oct 8, 2015, and April 26, 2018, 147 eligible patients were enrolled to the dose-expansion phase. The most common (in ≥20% of patients) treatment-emergent adverse events of any grade were epistaxis (102 [69%] of 147 patients), fatigue (82 [56%]), nausea (77 [52%]), alopecia (64 [44%]), conjunctivitis (63 [43%]), decreased appetite (53 [36%]), constipation (52 [35%]), diarrhoea (44 [30%]), vomiting (42 [29%]), peripheral neuropathy (33 [22%]), dry eye (32 [22%]), and abdominal pain (30 [20%]). The most common adverse events of grade 3 or worse were fatigue (14 [10%] of 147 patients), anaemia (eight [5%]), abdominal pain (six [4%]), hypokalaemia (six [4%]), conjunctivitis (five [3%]), hyponatraemia (five [3%]), and vomiting (five [3%]). 67 (46%) of 147 patients had a treatment-emergent serious adverse event. 39 (27%) of 147 patients had a treatment-emergent serious adverse event related to the study drug. Infusion-related reactions occurred in 17 (12%) of 147 patients. Across tumour types, the confirmed proportion of patients who achieved an objective response was 15·6% (95% CI 10·2-22·5; 23 of 147 patients). There were nine deaths across all study phases (three in the dose-escalation phase and six in the dose-expansion phase); only one case of pneumonia in the dose-expansion phase was considered possibly related to study treatment.Tisotumab vedotin has a manageable safety profile with encouraging preliminary antitumour activity across multiple tumour types in heavily pretreated patients. Continued evaluation of tisotumab vedotin is warranted in solid tumours.INTERPRETATIONSTisotumab vedotin has a manageable safety profile with encouraging preliminary antitumour activity across multiple tumour types in heavily pretreated patients. Continued evaluation of tisotumab vedotin is warranted in solid tumours.Genmab A/S.FUNDINGGenmab A/S. Summary Background Tisotumab vedotin is a first-in-human antibody–drug conjugate directed against tissue factor, which is expressed across multiple solid tumour types and is associated with poor clinical outcomes. We aimed to establish the safety, tolerability, pharmacokinetic profile, and antitumour activity of tisotumab vedotin in a mixed population of patients with locally advanced or metastatic (or both) solid tumours known to express tissue factor. Methods InnovaTV 201 is a phase 1–2, open-label, dose-escalation and dose-expansion study done at 21 centres in the USA and Europe. Patients (aged ≥18 years) had relapsed, advanced, or metastatic cancer of the ovary, cervix, endometrium, bladder, prostate, oesophagus, squamous cell carcinoma of the head and neck or non-small-cell lung cancer; an Eastern Cooperative Oncology Group performance status of 0–1; and had relapsed after or were not eligible to receive the available standard of care. No specific tissue factor expression level was required for inclusion. In the dose-escalation phase, patients were treated with tisotumab vedotin between 0·3 and 2·2 mg/kg intravenously once every 3 weeks in a traditional 3 + 3 design. In the dose-expansion phase, patients were treated at the recommended phase 2 dose. The primary endpoint was the incidence of adverse events, including serious adverse events, infusion-related, treatment-related and those of grade 3 or worse, and study drug-related adverse events, analysed in all patients who received at least one dose of tisotumab vedotin (full analysis population). This trial is registered with ClinicalTrials.gov, number NCT02001623, and is closed to new participants with follow-up ongoing. Findings Between Dec 9, 2013, and May 18, 2015, 27 eligible patients were enrolled to the dose-escalation phase. Dose-limiting toxicities, including grade 3 type 2 diabetes mellitus, mucositis, and neutropenic fever, were seen at the 2·2 mg/kg dose; therefore, 2·0 mg/kg of tisotumab vedotin intravenously once every 3 weeks was established as the recommended phase 2 dose. Between Oct 8, 2015, and April 26, 2018, 147 eligible patients were enrolled to the dose-expansion phase. The most common (in ≥20% of patients) treatment-emergent adverse events of any grade were epistaxis (102 [69%] of 147 patients), fatigue (82 [56%]), nausea (77 [52%]), alopecia (64 [44%]), conjunctivitis (63 [43%]), decreased appetite (53 [36%]), constipation (52 [35%]), diarrhoea (44 [30%]), vomiting (42 [29%]), peripheral neuropathy (33 [22%]), dry eye (32 [22%]), and abdominal pain (30 [20%]). The most common adverse events of grade 3 or worse were fatigue (14 [10%] of 147 patients), anaemia (eight [5%]), abdominal pain (six [4%]), hypokalaemia (six [4%]), conjunctivitis (five [3%]), hyponatraemia (five [3%]), and vomiting (five [3%]). 67 (46%) of 147 patients had a treatment-emergent serious adverse event. 39 (27%) of 147 patients had a treatment-emergent serious adverse event related to the study drug. Infusion-related reactions occurred in 17 (12%) of 147 patients. Across tumour types, the confirmed proportion of patients who achieved an objective response was 15·6% (95% CI 10·2–22·5; 23 of 147 patients). There were nine deaths across all study phases (three in the dose-escalation phase and six in the dose-expansion phase); only one case of pneumonia in the dose-expansion phase was considered possibly related to study treatment. Interpretations Tisotumab vedotin has a manageable safety profile with encouraging preliminary antitumour activity across multiple tumour types in heavily pretreated patients. Continued evaluation of tisotumab vedotin is warranted in solid tumours. Funding Genmab A/S. |
| Author | Collins, Dearbhaile Spicer, James F Forster, Martin David Dean, Emma Rangwala, Reshma A Ang, Joo Ern Hong, David S Nielsen, Dorte Machiels, Jean-Pascal Arkenau, Hendrik-Tobias Jones, Robert Hugh Concin, Nicole Ghatta, Srinivas Lassen, Ulrik Yachnin, Jeffrey Thistlethwaite, Fiona C de Bono, Johann S Windfeld, Kristian Mau-Sørensen, Paul Morten Slomovitz, Brian M Plummer, Ruth |
| Author_xml | – sequence: 1 givenname: Johann S surname: de Bono fullname: de Bono, Johann S email: johann.de-bono@irc.ac.uk organization: The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, UK – sequence: 2 givenname: Nicole surname: Concin fullname: Concin, Nicole organization: BGOG and Catholic University of Leuven, Leuven Cancer Institute, Leuven, Belgium – sequence: 3 givenname: David S surname: Hong fullname: Hong, David S organization: Phase I Unit, The University of Texas MD Anderson Cancer Center, Houston, TX, USA – sequence: 4 givenname: Fiona C surname: Thistlethwaite fullname: Thistlethwaite, Fiona C organization: Department of Medical Oncology, The Christie NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK – sequence: 5 givenname: Jean-Pascal surname: Machiels fullname: Machiels, Jean-Pascal organization: Service d'Oncologie Médicale, Institut Roi Albert II, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale, Université Catholique de Louvain, Brussels, Belgium – sequence: 6 givenname: Hendrik-Tobias surname: Arkenau fullname: Arkenau, Hendrik-Tobias organization: Sarah Cannon Research Institute, University College of London, London, UK – sequence: 7 givenname: Ruth surname: Plummer fullname: Plummer, Ruth organization: Sir Bobby Robson Cancer Trials Research Centre, Freeman Hospital, Newcastle University, Newcastle, UK – sequence: 8 givenname: Robert Hugh surname: Jones fullname: Jones, Robert Hugh organization: Velindre Cancer Centre and Cardiff University, Cardiff, UK – sequence: 9 givenname: Dorte surname: Nielsen fullname: Nielsen, Dorte organization: Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Cophenhagen, Denmark – sequence: 10 givenname: Kristian surname: Windfeld fullname: Windfeld, Kristian organization: Genmab, Copenhagen, Denmark – sequence: 11 givenname: Srinivas surname: Ghatta fullname: Ghatta, Srinivas organization: Genmab US, Princeton, NJ, USA – sequence: 12 givenname: Brian M surname: Slomovitz fullname: Slomovitz, Brian M organization: Division of Gynecologic Oncology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA – sequence: 13 givenname: James F surname: Spicer fullname: Spicer, James F organization: Guy's Hospital, King's College London, London, UK – sequence: 14 givenname: Jeffrey surname: Yachnin fullname: Yachnin, Jeffrey organization: Karolinska University Hospital, Solna, Sweden – sequence: 15 givenname: Joo Ern surname: Ang fullname: Ang, Joo Ern organization: The Institute of Cancer Research, Royal Marsden NHS Foundation Trust, London, UK – sequence: 16 givenname: Paul Morten surname: Mau-Sørensen fullname: Mau-Sørensen, Paul Morten organization: Department of Oncology, Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark – sequence: 17 givenname: Martin David surname: Forster fullname: Forster, Martin David organization: UCL Cancer Institute, University College London Hospitals, London, UK – sequence: 18 givenname: Dearbhaile surname: Collins fullname: Collins, Dearbhaile organization: Department of Medical Oncology, Cork University Hospital, Cork, Ireland – sequence: 19 givenname: Emma surname: Dean fullname: Dean, Emma organization: Service d'Oncologie Médicale, Institut Roi Albert II, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale, Université Catholique de Louvain, Brussels, Belgium – sequence: 20 givenname: Reshma A surname: Rangwala fullname: Rangwala, Reshma A organization: Genmab US, Princeton, NJ, USA – sequence: 21 givenname: Ulrik surname: Lassen fullname: Lassen, Ulrik organization: Department of Oncology, Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30745090$$D View this record in MEDLINE/PubMed http://kipublications.ki.se/Default.aspx?queryparsed=id:140411248$$DView record from Swedish Publication Index (Karolinska Institutet) |
| BookMark | eNqNks1u1DAUhSNURH_gEUCW2EylBq7tJOOAAKGKn0qVWDCwtTzOjeo2sQfbmao7lux5Q54EZzLtYiRU5Ei27O-c2Ofew2zPOotZ9pTCCwq0evmVFnPIGRTljIpjDqKsc_4gO0jbRV4WQuxt1hOynx2GcAlA5xTKR9k-h3lRQg0H2a-FCS4OvVqSNTYuGkvSt1LRoI2BXJt4QVSzVlZjQ5wnPUYVYjrWJLjONCRp3eADmZ1Z69Zq8Z0woMeviCKt8SHmxuYXyd6ekH7okizZejwhqwsVkNA_P38zEr1R3ePsYau6gE-281H27eOHxenn_PzLp7PT9-e5LsU85orXDGteVW2FCAgqjbpNr6lZBaCWDVdagaC8aRmt20LXIFrkrUiHolSMH2X55BuucTUs5cqbXvkb6ZSR262rtEJZCAZlkfjZxK-8-zFgiLI3QWPXKYtuCJJRIWrBgVUJfb6DXqZobHrNSM0pT1WCRD3bUsOyx-buArc1ScDrCdDeheCxldqMibuUnDKdpCDHDpCbDpBjeSUVctMBkid1uaO-_cF9uneTDlP4a4NeBp16IJXdeNRRNs7c6_B2x0F3xhqtuiu8wXCXBZWBSZhMRg8qNg6jwZt_G_zHBf4CO6zwVg |
| CitedBy_id | crossref_primary_10_3348_kjr_2025_0416 crossref_primary_10_1186_s40364_025_00818_7 crossref_primary_10_1007_s11912_023_01463_9 crossref_primary_10_1038_s41392_022_00947_7 crossref_primary_10_1016_S1470_2045_21_00056_5 crossref_primary_10_1200_EDBK_281107 crossref_primary_10_1016_j_thromres_2020_01_019 crossref_primary_10_3390_pharmaceutics13101705 crossref_primary_10_1097_PPO_0000000000000627 crossref_primary_10_3389_fphar_2022_921385 crossref_primary_10_1016_j_urolonc_2023_08_020 crossref_primary_10_2147_BTT_S369783 crossref_primary_10_1177_17588359241277647 crossref_primary_10_1080_14712598_2020_1789096 crossref_primary_10_3390_cancers14133288 crossref_primary_10_1038_s41388_020_1244_1 crossref_primary_10_3389_fonc_2024_1323366 crossref_primary_10_1016_S1470_2045_18_30912_4 crossref_primary_10_1089_jop_2023_0069 crossref_primary_10_1158_1078_0432_CCR_23_1079 crossref_primary_10_1016_j_ygyno_2021_08_009 crossref_primary_10_1016_j_urolonc_2023_06_006 crossref_primary_10_1080_14656566_2022_2150966 crossref_primary_10_1093_procel_pwaf002 crossref_primary_10_3389_fonc_2024_1395784 crossref_primary_10_3390_md19060342 crossref_primary_10_1007_s11523_022_00872_3 crossref_primary_10_1016_j_isci_2023_107778 crossref_primary_10_3390_cancers14092125 crossref_primary_10_1002_psp4_12850 crossref_primary_10_3390_ijms26188941 crossref_primary_10_3390_cancers15123162 crossref_primary_10_3390_cancers13184652 crossref_primary_10_31083_j_fbl2912426 crossref_primary_10_1007_s11239_022_02662_0 crossref_primary_10_1158_1078_0432_CCR_21_1564 crossref_primary_10_1002_mco2_455 crossref_primary_10_1007_s40265_021_01633_8 crossref_primary_10_3892_mco_2024_2804 crossref_primary_10_3390_cancers15030713 crossref_primary_10_7759_cureus_87453 crossref_primary_10_3389_fimmu_2023_1335252 crossref_primary_10_3390_cancers17050834 crossref_primary_10_1038_s41598_020_59736_3 crossref_primary_10_3390_molecules25214964 crossref_primary_10_1177_11795549241260534 crossref_primary_10_1016_j_canlet_2021_03_009 crossref_primary_10_3390_molecules25204764 crossref_primary_10_1080_17425255_2022_2162383 crossref_primary_10_1097_ICO_0000000000003664 crossref_primary_10_1007_s40123_020_00280_8 crossref_primary_10_1097_ICU_0000000000001063 crossref_primary_10_1016_j_currproblcancer_2023_100952 crossref_primary_10_1080_13543784_2023_2179483 crossref_primary_10_3892_ol_2020_11774 crossref_primary_10_1002_jev2_12070 crossref_primary_10_1038_s41388_025_03448_3 crossref_primary_10_1016_j_preteyeres_2024_101302 crossref_primary_10_1038_s41598_024_71977_0 crossref_primary_10_3390_cancers13153839 crossref_primary_10_3390_cancers16132398 crossref_primary_10_1200_JCO_25_01235 crossref_primary_10_1097_PPO_0000000000000633 crossref_primary_10_1016_j_ijgc_2025_101639 crossref_primary_10_1016_j_survophthal_2023_10_002 crossref_primary_10_1016_j_bulcan_2025_02_004 crossref_primary_10_1038_s41571_020_0339_5 crossref_primary_10_3390_cancers14020391 crossref_primary_10_3390_cancers15143692 crossref_primary_10_1016_j_cllc_2021_07_011 crossref_primary_10_1016_j_apsb_2024_12_036 crossref_primary_10_1016_j_pharmthera_2021_108106 crossref_primary_10_1002_mco2_671 crossref_primary_10_1016_j_jaad_2024_08_036 crossref_primary_10_1007_s12094_025_04050_5 crossref_primary_10_3390_md21010024 crossref_primary_10_1016_j_semcancer_2021_03_031 crossref_primary_10_1080_14712598_2020_1776253 crossref_primary_10_1158_1078_0432_CCR_22_2981 crossref_primary_10_3389_fonc_2021_691685 crossref_primary_10_3390_cancers14030778 crossref_primary_10_1016_j_bone_2025_117566 crossref_primary_10_1172_JCI188492 crossref_primary_10_1007_s00108_019_00680_4 crossref_primary_10_3390_ijms26146815 crossref_primary_10_3892_ol_2025_15130 crossref_primary_10_1097_CJI_0000000000000507 crossref_primary_10_1007_s40259_024_00660_7 crossref_primary_10_1053_j_semnuclmed_2025_08_002 crossref_primary_10_1093_oncolo_oyae177 crossref_primary_10_1016_j_critrevonc_2023_104189 crossref_primary_10_3390_cancers12082223 crossref_primary_10_7759_cureus_34490 crossref_primary_10_1016_j_bbcan_2023_189053 crossref_primary_10_3390_ijms25052580 crossref_primary_10_1007_s40265_023_01934_0 crossref_primary_10_1038_s41392_020_0199_6 crossref_primary_10_1111_cas_16335 crossref_primary_10_1016_j_annemergmed_2024_10_015 crossref_primary_10_1186_s13045_021_01035_z crossref_primary_10_1016_j_ctrv_2022_102393 crossref_primary_10_1111_jog_16126 crossref_primary_10_1056_NEJMoa2313811 crossref_primary_10_1158_1078_0432_CCR_19_2962 crossref_primary_10_1007_s11864_022_01018_3 crossref_primary_10_1016_j_ctrv_2024_102867 crossref_primary_10_1016_j_jhepr_2025_101473 crossref_primary_10_1016_j_heliyon_2023_e21425 crossref_primary_10_1016_j_prp_2024_155136 crossref_primary_10_3389_fphar_2022_1093666 crossref_primary_10_1186_s40364_023_00504_6 crossref_primary_10_3390_ijms25031845 crossref_primary_10_3390_uro5020011 crossref_primary_10_3233_BLC_230070 crossref_primary_10_2147_CMAR_S294080 crossref_primary_10_1038_s41419_024_06837_w crossref_primary_10_1080_17425255_2019_1648431 crossref_primary_10_1111_cas_14857 crossref_primary_10_1007_s40135_024_00322_5 crossref_primary_10_1111_cas_14983 crossref_primary_10_1007_s40267_022_00939_1 crossref_primary_10_1016_j_gore_2024_101356 crossref_primary_10_1016_j_gore_2025_101676 crossref_primary_10_3892_or_2024_8854 crossref_primary_10_1016_j_eururo_2025_06_013 crossref_primary_10_3389_fonc_2024_1414112 crossref_primary_10_1158_1535_7163_MCT_24_0763 crossref_primary_10_1097_MOU_0000000000001263 crossref_primary_10_1007_s11523_020_00740_y crossref_primary_10_1038_s41598_025_14710_9 crossref_primary_10_1080_14737140_2022_2075348 crossref_primary_10_1007_s44178_024_00113_9 crossref_primary_10_1093_cvr_cvaf095 crossref_primary_10_1016_j_apsb_2021_10_028 crossref_primary_10_1186_s12943_024_01963_7 crossref_primary_10_1200_EDBK_431766 crossref_primary_10_1002_psp4_13007 crossref_primary_10_1016_j_critrevonc_2022_103851 crossref_primary_10_1016_j_humpath_2025_105926 crossref_primary_10_1016_j_addr_2021_113969 crossref_primary_10_1177_10781552221139775 crossref_primary_10_1080_14656566_2022_2084689 crossref_primary_10_3390_cancers15010263 crossref_primary_10_1016_j_yao_2023_01_010 crossref_primary_10_1016_j_gore_2024_101525 crossref_primary_10_1016_j_jaad_2024_07_1463 crossref_primary_10_3892_ijmm_2019_4418 crossref_primary_10_3390_cancers13133126 crossref_primary_10_3390_cancers13112841 |
| Cites_doi | 10.1038/sj.bjc.6605760 10.1007/s10585-011-9401-0 10.1016/j.ejca.2008.10.026 10.1200/JCO.2009.22.6324 10.1016/j.acthis.2008.11.024 10.1016/j.thromres.2013.09.016 10.1016/S0090-4295(03)00768-4 10.1016/j.coi.2016.02.008 10.1158/1078-0432.CCR-11-1425 10.1158/0008-5472.CAN-13-2440 10.1080/07357900802527247 10.1158/1535-7163.MCT-14-0798 10.3389/fimmu.2013.00076 10.1158/1538-7445.AM2015-2469 10.1002/ijc.23240 10.1182/blood-2016-02-699850 10.1097/PGP.0b013e3181ff9234 10.1186/1471-2407-11-263 10.1016/j.jss.2014.03.053 10.1002/anie.201702675 10.1182/blood-2011-06-317685 10.1002/(SICI)1097-0215(19980220)79:1<19::AID-IJC4>3.0.CO;2-Z 10.1080/19420862.2016.1156829 10.1158/1535-7163.MCT-15-0693 10.1158/1078-0432.CCR-04-0866 10.1055/s-0035-1556048 |
| ContentType | Journal Article |
| Copyright | 2019 Elsevier Ltd Elsevier Ltd Copyright © 2019 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Mar 2019 |
| Copyright_xml | – notice: 2019 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2019 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Mar 2019 |
| DBID | AAYXX CITATION NPM 3V. 7RV 7TO 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 ADTPV AOWAS D8T ZZAVC |
| DOI | 10.1016/S1470-2045(18)30859-3 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) ProQuest Nursing & Allied Health Database Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic SwePub SwePub Articles SWEPUB Freely available online SwePub Articles full text |
| DatabaseTitle | CrossRef PubMed Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic Oncogenes and Growth Factors Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: ProQuest Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1474-5488 |
| EndPage | 393 |
| ExternalDocumentID | oai_swepub_ki_se_482054 30745090 10_1016_S1470_2045_18_30859_3 S1470204518308593 1_s2_0_S1470204518308593 |
| Genre | Journal Article |
| GrantInformation | Genmab A/S. |
| GroupedDBID | --- --K --M -RU .1- .55 .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4CK 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABMAC ABMZM ABUWG ABWVN ACGFS ACIEU ACLOT ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEVXI AFKRA AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OC~ OO- OZT P-8 P-9 P2P PCD PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO R2- ROL RPZ SDG SEL SES SPCBC SSH SSZ T5K TLN UKHRP UV1 WOW X7M XBR Z5R ~HD 3V. AACTN AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF ABLVK ABYKQ AHPSJ AJBFU ZA5 9DU AAYXX AFFHD CITATION NPM 7TO 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO ADTPV AOWAS D8T ZZAVC |
| ID | FETCH-LOGICAL-c587t-a392e9366f6ee0e0a0a09f74592600abd3aca0813df219f4c908fe3f800a85a23 |
| IEDL.DBID | 7RV |
| ISICitedReferencesCount | 187 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000459953700045&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1470-2045 1474-5488 |
| IngestDate | Tue Nov 25 03:38:17 EST 2025 Sun Sep 28 09:39:32 EDT 2025 Tue Oct 07 05:38:25 EDT 2025 Wed Feb 19 02:33:48 EST 2025 Sat Nov 29 07:07:06 EST 2025 Tue Nov 18 20:43:06 EST 2025 Fri Feb 23 02:49:08 EST 2024 Sun Feb 23 10:18:52 EST 2025 Tue Oct 14 19:35:42 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| License | Copyright © 2019 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c587t-a392e9366f6ee0e0a0a09f74592600abd3aca0813df219f4c908fe3f800a85a23 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | http://kipublications.ki.se/Default.aspx?queryparsed=id:140411248 |
| PMID | 30745090 |
| PQID | 2187133080 |
| PQPubID | 46089 |
| PageCount | 11 |
| ParticipantIDs | swepub_primary_oai_swepub_ki_se_482054 proquest_miscellaneous_2188983026 proquest_journals_2187133080 pubmed_primary_30745090 crossref_citationtrail_10_1016_S1470_2045_18_30859_3 crossref_primary_10_1016_S1470_2045_18_30859_3 elsevier_sciencedirect_doi_10_1016_S1470_2045_18_30859_3 elsevier_clinicalkeyesjournals_1_s2_0_S1470204518308593 elsevier_clinicalkey_doi_10_1016_S1470_2045_18_30859_3 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-03-01 |
| PublicationDateYYYYMMDD | 2019-03-01 |
| PublicationDate_xml | – month: 03 year: 2019 text: 2019-03-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The lancet oncology |
| PublicationTitleAlternate | Lancet Oncol |
| PublicationYear | 2019 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Cocco, Hu, Richter (bib10) 2010; 103 Cocco, Varughese, Buza (bib14) 2011; 28 Yao, Ryan, Francis, Kohli, Taubman, Khorana (bib13) 2009; 27 Eisenhauer, Therasse, Bogaerts (bib24) 2009; 45 Kasthuri, Taubman, Mackman (bib5) 2009; 27 Versteeg (bib6) 2015; 41 Koomagi, Volm (bib8) 1998; 79 Nitori, Ino, Nakanishi (bib19) 2005; 11 Cocco, Varughese, Buza (bib7) 2011; 11 Fadare, Renshaw, Liang (bib11) 2011; 30 de Goeij, Satijn, Freitag (bib20) 2015; 14 van den Berg, Osanto, Reitsma, Versteeg (bib3) 2012; 119 Fanale, Forero-Torres, Rosenblatt (bib26) 2012; 18 Donaghy (bib25) 2016; 8 Ahmed, Abate, Song (bib9) 2017; 56 Seidel, Schlegel, Lang (bib22) 2013; 4 Chen, Gopal, Smith (bib2) 2016; 128 de Goeij, Lambert (bib21) 2016; 40 Chen, Luo, Tan (bib17) 2010; 112 Breij, de Goeij, Verploegen (bib1) 2014; 74 Patry, Hovington, Larue, Harel, Fradet, Lacombe (bib18) 2008; 122 Motoori, Yano, Tomita (bib16) 2014; 191 Chu (bib4) 2011; 2011 Weekes, Lamberts, Borad (bib27) 2016; 15 Abu Saadeh, Norris, O'Toole (bib15) 2013; 132 Akashi, Furuya, Ohta, Fuse (bib12) 2003; 62 Gardai, Epp, Law (bib23) 2015; 75 Versteeg (10.1016/S1470-2045(18)30859-3_bib6) 2015; 41 Gardai (10.1016/S1470-2045(18)30859-3_bib23) 2015; 75 Motoori (10.1016/S1470-2045(18)30859-3_bib16) 2014; 191 Ahmed (10.1016/S1470-2045(18)30859-3_bib9) 2017; 56 de Goeij (10.1016/S1470-2045(18)30859-3_bib21) 2016; 40 Donaghy (10.1016/S1470-2045(18)30859-3_bib25) 2016; 8 Chen (10.1016/S1470-2045(18)30859-3_bib17) 2010; 112 Breij (10.1016/S1470-2045(18)30859-3_bib1) 2014; 74 Akashi (10.1016/S1470-2045(18)30859-3_bib12) 2003; 62 Eisenhauer (10.1016/S1470-2045(18)30859-3_bib24) 2009; 45 Chen (10.1016/S1470-2045(18)30859-3_bib2) 2016; 128 van den Berg (10.1016/S1470-2045(18)30859-3_bib3) 2012; 119 Cocco (10.1016/S1470-2045(18)30859-3_bib14) 2011; 28 Abu Saadeh (10.1016/S1470-2045(18)30859-3_bib15) 2013; 132 Patry (10.1016/S1470-2045(18)30859-3_bib18) 2008; 122 Nitori (10.1016/S1470-2045(18)30859-3_bib19) 2005; 11 Chu (10.1016/S1470-2045(18)30859-3_bib4) 2011; 2011 Kasthuri (10.1016/S1470-2045(18)30859-3_bib5) 2009; 27 Cocco (10.1016/S1470-2045(18)30859-3_bib7) 2011; 11 Fadare (10.1016/S1470-2045(18)30859-3_bib11) 2011; 30 Koomagi (10.1016/S1470-2045(18)30859-3_bib8) 1998; 79 Yao (10.1016/S1470-2045(18)30859-3_bib13) 2009; 27 Fanale (10.1016/S1470-2045(18)30859-3_bib26) 2012; 18 Cocco (10.1016/S1470-2045(18)30859-3_bib10) 2010; 103 Weekes (10.1016/S1470-2045(18)30859-3_bib27) 2016; 15 Seidel (10.1016/S1470-2045(18)30859-3_bib22) 2013; 4 de Goeij (10.1016/S1470-2045(18)30859-3_bib20) 2015; 14 |
| References_xml | – volume: 11 start-page: 2531 year: 2005 end-page: 2539 ident: bib19 article-title: Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma publication-title: Clin Cancer Res – volume: 103 start-page: 812 year: 2010 end-page: 819 ident: bib10 article-title: hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma publication-title: Br J Cancer – volume: 4 start-page: 76 year: 2013 ident: bib22 article-title: Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies publication-title: Front Immunol – volume: 122 start-page: 1592 year: 2008 end-page: 1597 ident: bib18 article-title: Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer publication-title: Int J Cancer – volume: 14 start-page: 1130 year: 2015 end-page: 1140 ident: bib20 article-title: High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates publication-title: Mol Cancer Ther – volume: 128 start-page: 1562 year: 2016 end-page: 1566 ident: bib2 article-title: Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma publication-title: Blood – volume: 27 start-page: 4834 year: 2009 end-page: 4838 ident: bib5 article-title: Role of tissue factor in cancer publication-title: J Clin Oncol – volume: 191 start-page: 99 year: 2014 end-page: 105 ident: bib16 article-title: Tissue factor predicts response to chemotherapy in esophageal cancer publication-title: J Surg Res – volume: 74 start-page: 1214 year: 2014 end-page: 1226 ident: bib1 article-title: An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors publication-title: Cancer Res – volume: 62 start-page: 1078 year: 2003 end-page: 1082 ident: bib12 article-title: Tissue factor expression and prognosis in patients with metastatic prostate cancer publication-title: Urology – volume: 41 start-page: 747 year: 2015 end-page: 755 ident: bib6 article-title: Tissue factor: old and new links with cancer biology publication-title: Semin Thromb Hemost – volume: 28 start-page: 689 year: 2011 end-page: 700 ident: bib14 article-title: Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor publication-title: Clin Exp Metastasis – volume: 2011 start-page: 367284 year: 2011 ident: bib4 article-title: Tissue factor, blood coagulation, and beyond: an overview publication-title: Int J Inflam – volume: 40 start-page: 14 year: 2016 end-page: 23 ident: bib21 article-title: New developments for antibody-drug conjugate-based therapeutic approaches publication-title: Curr Opin Immunol – volume: 15 start-page: 439 year: 2016 end-page: 447 ident: bib27 article-title: Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer publication-title: Mol Cancer Ther – volume: 119 start-page: 924 year: 2012 end-page: 932 ident: bib3 article-title: The relationship between tissue factor and cancer progression: insights from bench and bedside publication-title: Blood – volume: 8 start-page: 659 year: 2016 end-page: 671 ident: bib25 article-title: Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates publication-title: MAbs – volume: 30 start-page: 252 year: 2011 end-page: 261 ident: bib11 article-title: Expression of tissue factor and heparanase in endometrial clear cell carcinoma: possible role for tissue factor in thromboembolic events publication-title: Int J Gynecol Pathol – volume: 56 start-page: 10681 year: 2017 end-page: 10685 ident: bib9 article-title: Isolation, detection, and antigen-based profiling of circulating tumor cells using a size-dictated immunocapture chip publication-title: Angew Chem Int Ed Engl – volume: 75 start-page: 2469 year: 2015 ident: bib23 article-title: Brentuximab vedotin-mediated immunogenic cell death publication-title: Cancer Res – volume: 18 start-page: 248 year: 2012 end-page: 255 ident: bib26 article-title: A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies publication-title: Clin Cancer Res – volume: 112 start-page: 233 year: 2010 end-page: 239 ident: bib17 article-title: Immunolocalisation of tissue factor in esophageal cancer is correlated with intratumoral angiogenesis and prognosis of the patient publication-title: Acta Histochem – volume: 132 start-page: 627 year: 2013 end-page: 634 ident: bib15 article-title: Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer- relationship with venous thrombosis risk publication-title: Thromb Res – volume: 45 start-page: 228 year: 2009 end-page: 247 ident: bib24 article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) publication-title: Eur J Cancer – volume: 79 start-page: 19 year: 1998 end-page: 22 ident: bib8 article-title: Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis publication-title: Int J Cancer – volume: 27 start-page: 430 year: 2009 end-page: 434 ident: bib13 article-title: Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study publication-title: Cancer Invest – volume: 11 start-page: 263 year: 2011 ident: bib7 article-title: Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor publication-title: BMC Cancer – volume: 103 start-page: 812 year: 2010 ident: 10.1016/S1470-2045(18)30859-3_bib10 article-title: hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma publication-title: Br J Cancer doi: 10.1038/sj.bjc.6605760 – volume: 28 start-page: 689 year: 2011 ident: 10.1016/S1470-2045(18)30859-3_bib14 article-title: Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor publication-title: Clin Exp Metastasis doi: 10.1007/s10585-011-9401-0 – volume: 45 start-page: 228 year: 2009 ident: 10.1016/S1470-2045(18)30859-3_bib24 article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) publication-title: Eur J Cancer doi: 10.1016/j.ejca.2008.10.026 – volume: 2011 start-page: 367284 year: 2011 ident: 10.1016/S1470-2045(18)30859-3_bib4 article-title: Tissue factor, blood coagulation, and beyond: an overview publication-title: Int J Inflam – volume: 27 start-page: 4834 year: 2009 ident: 10.1016/S1470-2045(18)30859-3_bib5 article-title: Role of tissue factor in cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2009.22.6324 – volume: 112 start-page: 233 year: 2010 ident: 10.1016/S1470-2045(18)30859-3_bib17 article-title: Immunolocalisation of tissue factor in esophageal cancer is correlated with intratumoral angiogenesis and prognosis of the patient publication-title: Acta Histochem doi: 10.1016/j.acthis.2008.11.024 – volume: 132 start-page: 627 year: 2013 ident: 10.1016/S1470-2045(18)30859-3_bib15 article-title: Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer- relationship with venous thrombosis risk publication-title: Thromb Res doi: 10.1016/j.thromres.2013.09.016 – volume: 62 start-page: 1078 year: 2003 ident: 10.1016/S1470-2045(18)30859-3_bib12 article-title: Tissue factor expression and prognosis in patients with metastatic prostate cancer publication-title: Urology doi: 10.1016/S0090-4295(03)00768-4 – volume: 40 start-page: 14 year: 2016 ident: 10.1016/S1470-2045(18)30859-3_bib21 article-title: New developments for antibody-drug conjugate-based therapeutic approaches publication-title: Curr Opin Immunol doi: 10.1016/j.coi.2016.02.008 – volume: 18 start-page: 248 year: 2012 ident: 10.1016/S1470-2045(18)30859-3_bib26 article-title: A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-1425 – volume: 74 start-page: 1214 year: 2014 ident: 10.1016/S1470-2045(18)30859-3_bib1 article-title: An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-13-2440 – volume: 27 start-page: 430 year: 2009 ident: 10.1016/S1470-2045(18)30859-3_bib13 article-title: Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study publication-title: Cancer Invest doi: 10.1080/07357900802527247 – volume: 14 start-page: 1130 year: 2015 ident: 10.1016/S1470-2045(18)30859-3_bib20 article-title: High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-14-0798 – volume: 4 start-page: 76 year: 2013 ident: 10.1016/S1470-2045(18)30859-3_bib22 article-title: Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies publication-title: Front Immunol doi: 10.3389/fimmu.2013.00076 – volume: 75 start-page: 2469 issue: suppl 15 year: 2015 ident: 10.1016/S1470-2045(18)30859-3_bib23 article-title: Brentuximab vedotin-mediated immunogenic cell death publication-title: Cancer Res doi: 10.1158/1538-7445.AM2015-2469 – volume: 122 start-page: 1592 year: 2008 ident: 10.1016/S1470-2045(18)30859-3_bib18 article-title: Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer publication-title: Int J Cancer doi: 10.1002/ijc.23240 – volume: 128 start-page: 1562 year: 2016 ident: 10.1016/S1470-2045(18)30859-3_bib2 article-title: Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma publication-title: Blood doi: 10.1182/blood-2016-02-699850 – volume: 30 start-page: 252 year: 2011 ident: 10.1016/S1470-2045(18)30859-3_bib11 article-title: Expression of tissue factor and heparanase in endometrial clear cell carcinoma: possible role for tissue factor in thromboembolic events publication-title: Int J Gynecol Pathol doi: 10.1097/PGP.0b013e3181ff9234 – volume: 11 start-page: 263 year: 2011 ident: 10.1016/S1470-2045(18)30859-3_bib7 article-title: Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor publication-title: BMC Cancer doi: 10.1186/1471-2407-11-263 – volume: 191 start-page: 99 year: 2014 ident: 10.1016/S1470-2045(18)30859-3_bib16 article-title: Tissue factor predicts response to chemotherapy in esophageal cancer publication-title: J Surg Res doi: 10.1016/j.jss.2014.03.053 – volume: 56 start-page: 10681 year: 2017 ident: 10.1016/S1470-2045(18)30859-3_bib9 article-title: Isolation, detection, and antigen-based profiling of circulating tumor cells using a size-dictated immunocapture chip publication-title: Angew Chem Int Ed Engl doi: 10.1002/anie.201702675 – volume: 119 start-page: 924 year: 2012 ident: 10.1016/S1470-2045(18)30859-3_bib3 article-title: The relationship between tissue factor and cancer progression: insights from bench and bedside publication-title: Blood doi: 10.1182/blood-2011-06-317685 – volume: 79 start-page: 19 year: 1998 ident: 10.1016/S1470-2045(18)30859-3_bib8 article-title: Tissue-factor expression in human non-small-cell lung carcinoma measured by immunohistochemistry: correlation between tissue factor and angiogenesis publication-title: Int J Cancer doi: 10.1002/(SICI)1097-0215(19980220)79:1<19::AID-IJC4>3.0.CO;2-Z – volume: 8 start-page: 659 year: 2016 ident: 10.1016/S1470-2045(18)30859-3_bib25 article-title: Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates publication-title: MAbs doi: 10.1080/19420862.2016.1156829 – volume: 15 start-page: 439 year: 2016 ident: 10.1016/S1470-2045(18)30859-3_bib27 article-title: Phase I study of DMOT4039A, an antibody-drug conjugate targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-15-0693 – volume: 11 start-page: 2531 year: 2005 ident: 10.1016/S1470-2045(18)30859-3_bib19 article-title: Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-04-0866 – volume: 41 start-page: 747 year: 2015 ident: 10.1016/S1470-2045(18)30859-3_bib6 article-title: Tissue factor: old and new links with cancer biology publication-title: Semin Thromb Hemost doi: 10.1055/s-0035-1556048 |
| SSID | ssj0017105 |
| Score | 2.6432467 |
| Snippet | Tisotumab vedotin is a first-in-human antibody–drug conjugate directed against tissue factor, which is expressed across multiple solid tumour types and is... SummaryBackgroundTisotumab vedotin is a first-in-human antibody–drug conjugate directed against tissue factor, which is expressed across multiple solid tumour... Tisotumab vedotin is a first-in-human antibody-drug conjugate directed against tissue factor, which is expressed across multiple solid tumour types and is... Summary Background Tisotumab vedotin is a first-in-human antibody–drug conjugate directed against tissue factor, which is expressed across multiple solid... |
| SourceID | swepub proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 383 |
| SubjectTerms | Alopecia Angiogenesis Appetite loss Biology Bladder cancer Cell cycle Cervical cancer Conjunctivitis Constipation Cytotoxicity Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diarrhea Drug dosages Endometrial cancer Endometrium Esophagus Fatigue Fever Head & neck cancer Hematology, Oncology, and Palliative Medicine Hypoxia Infections Inflammatory bowel disease Lung cancer Medical prognosis Metastases Metastasis Monoclonal antibodies Mucositis Nausea Neutropenia Oncology Ovarian cancer Pain Patients Peripheral neuropathy Prostate Prostate cancer Sepsis Solid tumors Squamous cell carcinoma Studies Targeted cancer therapy Tumors Vomiting |
| Title | Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1470204518308593 https://www.clinicalkey.es/playcontent/1-s2.0-S1470204518308593 https://dx.doi.org/10.1016/S1470-2045(18)30859-3 https://www.ncbi.nlm.nih.gov/pubmed/30745090 https://www.proquest.com/docview/2187133080 https://www.proquest.com/docview/2188983026 http://kipublications.ki.se/Default.aspx?queryparsed=id:140411248 |
| Volume | 20 |
| WOSCitedRecordID | wos000459953700045&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Health & Medical Collection (ProQuest) customDbUrl: eissn: 1474-5488 dateEnd: 20251013 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 7X7 dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-5488 dateEnd: 20251013 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: BENPR dateStart: 20000901 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Nursing & Allied Health Database customDbUrl: eissn: 1474-5488 dateEnd: 20251013 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 7RV dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database (ProQuest) customDbUrl: eissn: 1474-5488 dateEnd: 20251013 omitProxy: false ssIdentifier: ssj0017105 issn: 1470-2045 databaseCode: 8C1 dateStart: 20000901 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELaghYoLj_IKlMpICLVSTZO1E9tcEFSt4MCqKku1N8tJbBGVZpdNthI3jtz5h_wSxo6TSryKhHZlrZKMvLsznvlsj79B6EkqYytE6VJx8pywURkTrWE8gsJtnlEI-ib3xSb4eCymU3kYFtyakFbZ-0TvqMtZ4dbIdyEUufkUAJwX80_EVY1yu6uhhMZltJo4bAz2zI-Oh10E3qUwJozHxNGun5_g2X03XNxKxDZ1NF-E_ik2_Yo9fyIW9cHo4Mb__oyb6HqAofhlZze30CVTr6OrXWHKz-to7W3Ycr-Nvk6qZtYuT3WOzwxMYasawzvQsTbYrePiPpEAzxb41LTanVKqCgxmXZUYZKG3Bm-98QVYJ8cY0MD2c6yxrQB6kqomvlDgDvbJjT5b1Ozg-QeIrzj5_uXbCPvSInfQ-4P9yd5rEso3kCIVvCUaoJeRNMtsZkxsYg0vaTlLpSPF13lJdaEBkdDSgtu0rJCxsIZagLBapHpE76KVelab-wibUicWns1BhOVc6pyWMLWNNc25pkxGiPWKU0XgNnclNj6qIYnN6Vs5fatEKK9vRSP0bBCbd-QeFwlkvVWo_uQq-FoF4eciQf47QdMEj9GoRDUjFXfSThhcreeii5AYJAMo6sDOv3S60dugGvo5N8AIPR5ug09xG0W6NrOlf0ZIRwyXReheZ_DD_wMxgQHIBOmn3QgY7jii8nDpBD4ZxQBdpuzB37_FQ3QNrE52aX0baKVdLM0jdKU4a6tmsenHs2un3LcCWrGXbKLVV_vjw6MfA99Q2g |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb5VAFD5p6qNufNQXWnVM1LRJaYEBBkyMMWrTm7Y3Jt6auxsHmIlEC9fLvTXduXTv__BH-Us8MwM08VU3XRhYEOBkyHAe34Ez3wF4EKWeSpJCl-JkmRsGhecKgfaIL1xlMcWgLzPTbIINh8l4nL5agG_dWhhdVtn5ROOoizrX38g3MRTpfAoBztPJR1d3jdJ_V7sWGlYtduTRJ0zZmieDF_h-HwbB1svR82237Srg5lHCZq5ARCBTGscqltKTnsAtVSyMUs3VLrKCilxgoKSFQmtWYZ56iZJUIbISSSQ00QG6_DPox5lO9ti4T_B8Zksm_ZB5rqZ5P14xtPm6P7nqJ2tU04q59E-x8Fes-xORqQl-W5f-t2m7DBdbmE2eWbu4AguyWoZztvHm0TKc32tLCq7Cl1HZ1LP5gcjIocQUvawI7i3dbEP0d2rSFUqQekoO5EzoVVhlTtBsy4KgLI7WkNWBaTA7ekMQ7aw9JoKoEqG1W1auaYS4TkzxpqmGletk8g7xA_G_f_4aENM65Rrsn8qMXIfFqq7kTSCyEL7CezMUCTOWiowWmLp7gmZM0DB1IOwUhectd7tuIfKB90V6Wr-41i_uJ9zoF6cObPRiE0tecpJA3Gkh71bmYizhGF5PEmS_E5RN6xEb7vMm4J6V1sIYSgzXngNJL9mCPgvm_mXQlU7neT_OscI7cL-_jD5T_wgTlazn5p4k1cR3sQM3rIH184MxL0QQjdKPrMX1VzQRe3vqPR5JHiJ6jsJbf3-Ke7C0Pdrb5buD4c5tuIAamNoSxhVYnE3n8g6czQ9nZTO9a3wJgbenbYU_AN1KqPo |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbtNAFL2qClRseJRXoMAgAWqlmtoZxx4jIYRaIqJCVIkUdTeM7RlhQe0QO0XdsWTP3_Rz-iXcO35U4lU2XaBkEdm-mmh8H2fsM-cCPBxErhEiJSpOHDt-P3UdpTAe8YabOOBY9HVsm02E47HY24t2FuCo3QtDtMo2J9pEnRYJPSPfwFJE6ylSQTQNLWJna_h8-tmhDlL0prVtp1G7yLY-_ILLt_LZaAvv9aN-f_hysvnKaToMOMlAhJWjEB3oiAeBCbR2tavwE5nQH0Sk267ilKtEYdHkqcHINn4SucJobhBlKTFQJHqA6f9cyANOCz-x2dFLvLCmT3p-6Dok-X6ye2jjbXdw1RNrnCTGHP6nuvgr7v1J1NQWwuHl_3kKr8ClBn6zF3W8XIUFnS_Dhboh5-EyLL1pqAbX4NskK4tqvq9idqBx6Z7lDL-NDG3J6Pk1awkUrJixfV0p2p2VJQzDOUsZ2uJoJVsd2cazk3cMUdDaU6aYyRByO1nu2AaJ68ySOi1LVq-z6QfEFcw7_vq9z2xLleuweyYzcgMW8yLXt4DpVHkGr43RxI_DSMU8xSW9q3gcKu5HPfBbp5FJo-lOrUU-yY68R74mydekJ6T1Ncl78KQzm9aiJqcZBK1HynbHLtYYiWX3NMPwd4a6bDJlKT1Z9qVbW5MxlhirwdcD0Vk2YLAGef8y6Err_7Ib58T5e_CgO425lF6QqVwXc3uNiEgQL-jBzTrYuvnBWugjuEbrx3X0dWdIoL059BF_aekjqh74t__-L-7DEgaffD0ab9-Bi-iAUc1sXIHFajbXd-F8clBl5eyeTSsM3p91EP4Aws6xgQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tisotumab+vedotin+in+patients+with+advanced+or+metastatic+solid+tumours+%28InnovaTV+201%29%3A+a+first-in-human%2C+multicentre%2C+phase+1%E2%80%932+trial&rft.jtitle=The+lancet+oncology&rft.au=de+Bono%2C+Johann+S%2C+Prof&rft.au=Concin%2C+Nicole%2C+Prof&rft.au=Hong%2C+David+S%2C+MD&rft.au=Thistlethwaite%2C+Fiona+C%2C+MBBChir&rft.date=2019-03-01&rft.issn=1470-2045&rft.volume=20&rft.issue=3&rft.spage=383&rft.epage=393&rft_id=info:doi/10.1016%2FS1470-2045%2818%2930859-3&rft.externalDBID=ECK1-s2.0-S1470204518308593&rft.externalDocID=1_s2_0_S1470204518308593 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14702045%2FS1470204519X00030%2Fcov150h.gif |